Capital Fund Management S.A. Invests $2.08 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Capital Fund Management S.A. invested approximately $2.08 million in Arrowhead Pharmaceuticals by acquiring 163,146 shares in the first quarter, representing about 0.12% of the company's stock.
• A number of institutional investors have increased their stakes in Arrowhead Pharmaceuticals, highlighting growing interest as hedge funds and institutional investors own 62.61% of the company's stock.
• Research analysts have mixed ratings for Arrowhead Pharmaceuticals, with a consensus rating of "Buy" and an average price target of $43.14, despite recent earnings results falling short of expectations.

Capital Fund Management S.A. bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 163,146 shares of the biotechnology company's stock, valued at approximately $2,078,000. Capital Fund Management S.A. owned about 0.12% of Arrowhead Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ARWR. Vanguard Group Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock worth $168,201,000 after acquiring an additional 1,018,273 shares during the period. Farallon Capital Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $11,821,000. Aberdeen Group plc lifted its position in shares of Arrowhead Pharmaceuticals by 138.4% during the 1st quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company's stock worth $13,668,000 after buying an additional 622,752 shares during the period. Two Sigma Investments LP lifted its position in shares of Arrowhead Pharmaceuticals by 281.3% during the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock worth $14,934,000 after buying an additional 586,062 shares during the period. Finally, Public Sector Pension Investment Board bought a new position in shares of Arrowhead Pharmaceuticals during the 1st quarter worth approximately $5,094,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Trading Down 2.7%

Shares of ARWR stock traded down $0.61 on Friday, reaching $21.73. 1,326,775 shares of the stock were exchanged, compared to its average volume of 1,960,266. The stock has a market cap of $3.00 billion, a PE ratio of -16.99 and a beta of 0.94. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $27.34. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The stock has a 50 day moving average price of $17.58 and a 200 day moving average price of $16.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same period in the prior year, the firm posted ($1.38) EPS. Equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Royal Bank Of Canada cut their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Finally, Citigroup cut their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $43.14.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 9,389 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $20.00, for a total transaction of $187,780.00. Following the completion of the sale, the insider owned 262,122 shares in the company, valued at $5,242,440. The trade was a 3.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.